NEW YORK and WALTHAM, Mass., Sept. 11, 2025 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (Nasdaq: DNTH), a clinical-stage biotechnology company dedicated to advancing the next generation of antibody complement therapeutics to treat severe autoimmune diseases (“Dianthus” or the “Company”), today announced that it closed its previously announced underwritten public offering of 7,627,879 shares of its common stock, including the full exercise by the underwriters of their option to purchase an additional 1,1 ...

NEW YORK and WALTHAM, Mass., Sept. 09, 2025 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (Nasdaq: DNTH), a clinical-stage biotechnology company dedicated to advancing the next generation of antibody complement therapeutics to treat severe autoimmune diseases (“Dianthus” or the “Company”), today announced the pricing of its previously announced upsized underwritten public offering of 6,487,879 shares of its common stock at a public offering price per share of $33.00 and, in lieu of common stock to certain ...

公司业务与产品进展 - 专注于开发自身免疫性疾病治疗方法的生物制药公司 [1] - 即将举行电话会议和网络直播讨论治疗全身性重症肌无力的Claseprubart (DNTH103)二期MaGic试验结果 [1] 市场评级与股价表现 - 古根海姆维持买入评级并将目标价从92美元上调至100美元 [2] - 当前股价为31.71美元显示市场对试验结果存在增长预期 [2] 财务指标分析 - 市盈率为负10.74显示当前财务亏损状态 [3] - 市销率达228.18和企业价值与销售额比达225.73反映市场对未来销售潜力高度认可 [3] - 企业价值与经营现金流比为负10.93且收益率为负9.31% [3] - 债务权益比仅0.0044表明极低债务依赖度 [3] - 流动比率高达13.12显示强劲短期偿债能力 [4] 战略发展与市场定位 - 二期MaGic试验结果将成为公司发展的关键转折点 [2][4] - 财务指标与市场信心共同凸显公司面临的挑战与机遇 [4] - 即将举行的试验结果发布会将决定公司在生物制药领域的未来发展方向 [4]

PresentationI would now like to turn the call over to Marino Garcia, CEO of Dianthus Therapeutics. You may begin.Good morning, and welcome to the Dianthus Therapeutics Conference Call. My name is Michelle, and I'll be the operator for today's call. A slide presentation to accompany this call is available on the Investors section of the Dianthus Therapeutics website. Following the company's prepared remarks, we will move to Q&A session. Please note that today's call is being recorded.Marino GarciaPresident, ...

Photographer: Chris J. Ratcliffe/Bloomberg© 2024 Bloomberg Finance LPShares in homeware retailer Dunelm Group dropped as it announced rising full-year sales and profits despite a tough consumer landscape.At £11.66, Dunelm’s share price was last dealing 6% lower in Tuesday business.Revenues at the homeware retailer rose 3.8% in the 12 months to 28 June, to £1.8 billion, which it said reflected volume increases alongside a rise in average product prices.Dunelm said “the rise in average item values was primari ...

NEW YORK and WALTHAM, Mass., Sept. 08, 2025 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (Nasdaq: DNTH), a clinical-stage biotechnology company dedicated to advancing the next generation of antibody complement therapeutics to treat severe autoimmune diseases (“Dianthus” or the “Company”), today announced that it has commenced an underwritten public offering of $150 million of its shares of its common stock or, in lieu of common stock to certain investors that so choose, pre-funded warrants to purchase sh ...

Dianthus Therapeutics (NasdaqCM:DNTH) Update / Briefing September 08, 2025 08:00 AM ET Speaker0Good morning, and welcome to the Dianthus Therapeutics Conference Call. My name is Michelle, and I'll be the operator for today's call. A slide presentation to accompany this call is available on the Investors section of the Dianthus Therapeutics website. Following the company's prepared remarks, we will move to Q and A session. Please note that today's call is being recorded.I would now like to turn the call over ...

Claseprubart (DNTH103) Top-line Ph. 2 MaGic Results in Generalized Myasthenia Gravis September 8, 2025 Forward-looking statements Certain statements in this presentation ("Presentation"), other than purely historical information, may constitute "forward-looking statements" within the meaning of the federal securities laws, including for purposes of the safe harbor provisions under the United States Private Securities Litigation Reform Act of 1995, concerning Dianthus Therapeutics, Inc. (the "Company"). Thes ...

Claseprubart 300mg and 600mg Q2W doses both achieved statistically significant and clinically meaningful improvements in Myasthenia Gravis Activities of Daily Living (MG-ADL) and Quantitative Myasthenia Gravis (QMG) scores at Week 13 Claseprubart demonstrated a rapid and sustained onset of action, with both doses achieving statistically significant improvements in MG-ADL and QMG scores at Week 1 Claseprubart 300mg Q2W dose was also statistically significant and clinically meaningful across other key efficac ...

公司动态 - 公司将于2025年9月8日美国东部时间上午8点举行电话会议和网络直播 讨论claseprubart（DNTH103）治疗全身性重症肌无力（gMG）的2期MaGic试验结果 [1] 业务信息 - 公司为临床阶段生物技术公司 专注于开发新一代抗体补体疗法以治疗严重自身免疫性疾病 [1][3] - 公司致力于设计和提供具有改进选择性和效力的同类最佳单克隆抗体 [3] - 公司总部位于纽约市和马萨诸塞州沃尔瑟姆 由经验丰富的生物技术和制药高管团队组成 [3] 投资者关系 - 电话会议可通过预先注册获取拨入号码和个人PIN码参与 [2] - 网络直播可通过公司网站投资者与媒体部分访问 回放将在同一位置提供 [2]